Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27883933 | 0.86 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ARECQLMDM2 | |
| SCHEMBL22800969 | 0.85 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ARECQLMDM2 | |
| SCHEMBL4668605 | 0.85 | ALDH1A1 (0.79) | ALDH1A1MEN1KMT2ARECQLMDM2 | |
| SCHEMBL22800953 | 0.84 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2ARECQLMDM2 | |
| SCHEMBL4668659 | 0.84 | ALDH1A1 (0.77) | ALDH1A1MEN1KMT2ARECQLMDM2 | |
| SCHEMBL637424 | 0.83 | ALDH1A1 (0.76) | ALDH1A1MEN1KMT2ARECQLMDM2 | |
| SCHEMBL4667808 | 0.80 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2ARECQLMDM2 | |
| SCHEMBL4667126 | 0.80 | RECQL (0.76) | ALDH1A1MEN1KMT2ARECQLMDM2 | |
| SCHEMBL15923446 | 0.80 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ARECQLMDM2 | |
| SCHEMBL27901097 | 0.80 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2ARECQLMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | OREGON HEALTH AND SCIENCE UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| CN-102807568-A | Thiadiazole derivative DPP-IV (dipeptidyl peptidase IV) inhibitor | JIANGSU CHIA TAI TIANQING PHAR | 2012-12-05 | — | — | CN | disclosed |
| EP-1404675-B1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK AS (DK) | 2008-03-12 | — | — | EP | disclosed |
| US-7192952-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK, A/S (DK) | 2007-03-20 | — | — | US | disclosed |
| US-20050148606-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS B (DK) | 2005-07-07 | — | — | US | disclosed |
| US-6869947-B2 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| WO-2004033455-A2 | HEMISUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-04-22 | — | — | WO | disclosed |
| EP-1404675-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2003-06-05 | — | — | US | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148606-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | ALDH1A1 176/4885MEN1 4140/4885KMT2A 2165/4885 |
| US-20200399271-A1 | XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS | XDH, PNP, MAVS | ALDH1A1 1158/4885MEN1 4456/4885KMT2A 2568/4885 |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | XDH, PNP, MAVS | ALDH1A1 1158/4885MEN1 4456/4885KMT2A 2568/4885 |
| US-20030105077-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | ALDH1A1 55/4885MEN1 3558/4885KMT2A 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.